Didi Daboush
Co-founder & CEO
Claimed by owner MyBiotics Pharma
Former names: MyBiotix Pharma
Clinically Effective Microbiome and Probiotic Products
MyBiotics Pharma
www.prnewswire.com
•
Jan 24, 2022
MyBiotics announces successful completion of the Phase I trial for its MBX-SD-202 whole microbiome treatment, driving an innovative path to new restoration therapies using microbiome culturing technology
www.timesofisrael.com
•
Apr 6, 2021
MyBiotics, Hadassah to study impact of microbiome on cancer therapies
www.biospace.com
•
Feb 17, 2021
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health BioSpace
www.prnewswire.com
•
Feb 3, 2021
MyBiotics Pharma Receives Investment from Mii Fund, an Innovator in the Field of Dermatology
www.prnewswire.com
•
Nov 9, 2020
Galmed and MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol
www.geektime.com
•
Oct 26, 2020
Going on a gut feeling: Horizon 2020 grants $2.3M to Israel-based MyBiotics
en.globes.co.il
•
Mar 5, 2019
Ferring looks to Israel for innovative biotech
www.globes.co.il
•
Mar 12, 2018
Making good bacteria more resilient
www.pharmajournalist.com
•
Mar 6, 2018
MyBiotics signs second option agreement with Ferring Holding for the validation
About
MyBiotics Pharma is a microbiome company focused on bettering peoples lives and health by greatly improving on existing probiotic solutions. MyBiotics has developed a novel technological platform for the development of microbiome-related drugs and supplements.
The companys platform uses innovative formulation, delivery, and culturing methods designed to provide better viability and resistance, and potentially improved colonization and clinical results. Based on this proprietary innovation, MyBiotics has developed three main technologies: MyCrobe, SuperDonor, and Super Donor Select, which are all supported by MyLiveIn, a computational and AI technology platform.
After targeting specific medical indications, MyBiotics has now reached the clinical stage with three products. Based on the companys SuperDonor technology, its MBX-SD-201 and MBX-SD-202 products offer safe and reproducible microbiome restoration and may become an alternative for complete microbiome recovery and design using fecal microbiota transplantation.
MyBiotics has initiated significant collaborations and development agreements with a variety of pharmaceutical companies and clinical partners in the areas of C. diff, oncology, dermatology, and womens health.
The companys platform uses innovative formulation, delivery, and culturing methods designed to provide better viability and resistance, and potentially improved colonization and clinical results. Based on this proprietary innovation, MyBiotics has developed three main technologies: MyCrobe, SuperDonor, and Super Donor Select, which are all supported by MyLiveIn, a computational and AI technology platform.
After targeting specific medical indications, MyBiotics has now reached the clinical stage with three products. Based on the companys SuperDonor technology, its MBX-SD-201 and MBX-SD-202 products offer safe and reproducible microbiome restoration and may become an alternative for complete microbiome recovery and design using fecal microbiota transplantation.
MyBiotics has initiated significant collaborations and development agreements with a variety of pharmaceutical companies and clinical partners in the areas of C. diff, oncology, dermatology, and womens health.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
MBX-SD-201, MBX-SD-202
Geographic markets
Israel
News
(9)
www.prnewswire.com
•
Jan 24, 2022
MyBiotics announces successful completion of the Phase I trial for its MBX-SD-202 whole microbiome treatment, driving an innovative path to new restoration therapies using microbiome culturing technology
www.timesofisrael.com
•
Apr 6, 2021
MyBiotics, Hadassah to study impact of microbiome on cancer therapies
www.biospace.com
•
Feb 17, 2021
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health BioSpace
www.prnewswire.com
•
Feb 3, 2021
MyBiotics Pharma Receives Investment from Mii Fund, an Innovator in the Field of Dermatology
www.prnewswire.com
•
Nov 9, 2020
Galmed and MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol
www.geektime.com
•
Oct 26, 2020
Going on a gut feeling: Horizon 2020 grants $2.3M to Israel-based MyBiotics
en.globes.co.il
•
Mar 5, 2019
Ferring looks to Israel for innovative biotech
www.globes.co.il
•
Mar 12, 2018
Making good bacteria more resilient
www.pharmajournalist.com
•
Mar 6, 2018
MyBiotics signs second option agreement with Ferring Holding for the validation
The Team
(4)Motty Hershkowitz
CFO
EK
Eran Kosover
Chief Business Officer
LW
Lior Weissman
VP R&D
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
Seed
$320K
May 2015
$320K
Seed
$650K
Mar 2016
$650K
A Round
$8M
Aug 2018
$8M
Undisclosed Round
Undisclosed
Feb 2021
1 Investors
Undisclosed
Non-Equity Funding
Grant
$2.3M
Oct 2020
1 Grantors
$2.3M
Media gallery
(1)
Locations
Israel
Yitzhak Modai St 2, Rehovot, Israel
Locations
Israel
Yitzhak Modai St 2, Rehovot, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,